We go beyond making medical cannabis products. We make them accessible.
Panaxia is transforming pharmaceutical cannabis with consistent, effective, high-quality products that can be used the same way as other medicines.
We go beyond making medical cannabis products.
We make them accessible
Panaxia is transforming cannabis herbal substances into consistent, effective, high-quality products that can be used the same way as other medicines. To optimize patient compliance, we offer products with the unique properties of cannabinoids in many forms that chronic patients can use: tablets, suppositories, and the like. Our products are essential for patients who do not or cannot use medical cannabis via smoking.
It’s not just the cannabinoids that make our products effective.
It’s also the science
The power of our approach is to bring science and pharma standards to the still-evolving world of medical cannabis. Our substantial investment in research and development include a large internal R&D team and clinical partnerships with prominent medical centers.
The result of our well-established scientific approach – Products physicians feel confident recommending. And patients feel comfortable taking.
Bringing pharmaceutical standards to medical cannabis
We are the first company to be granted a license by the Israeli Ministry of Health to make pharmaceutical cannabis products under the stringent Good Manufacturing Practice (IMC-GMP) guidelines as well as EU-GMP standard certification required for commercial production and export of medical cannabis and its products to Europe.
These certifications ensure that our products are manufactured under the most demanding requirements for validation and standardization, so both patients and physicians alike can count on their consistency – no matter where they’re made.
Trusted collaboration with highly experienced strategic partners
When you’re revolutionizing an entire industry, it helps to have extraordinary strategic partners. Our network is extensive and ever growing, and it operates around the globe.
Collaborating with the world’s best medical cannabis companies and organizations enables us to quickly penetrate markets as they develop to bring pharmaceutical-grade cannabis products of the highest quality to as many people as we can
Panaxia Israel continues growth trend in the first quarter of 2021: reports record revenues of 19.7 million
May 31 2021 | Yahoo! 62% growth over the corresponding period the previous year and 16% over the previous quarter; The company is currently focused on
May 19 2021 | Yahoo! Following a successful launch at the local markets in Germany, France, and Cyprus, Panaxia’s medical cannabis-based products will be distributed in
May 3 2021 | Globes Panaxia Israel is selling its pharmacy, one of Israel’s largest for cannabis products, to IMC for NIS 20 million. Six months